Literature DB >> 20548128

Adenosine deaminase activity in COPD patients and healthy subjects.

Mohammad Taghi Goodarzi1, Mohammad Abdi, Heidar Tavilani, Ebrahim Nadi, Mojtaba Rashidi.   

Abstract

Chronic obstructive pulmonary disease (COPD) has been defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), as a disease state characterized by airflow limitation which is not fully reversible. COPD consists of emphysema which is the destruction and inflammation of the lung alveoli. Adenosine deaminase (ADA, E.C.3.5.4.4) converts adenosine to inosine. There are two isoenzymes of ADA in serum; ADA1 and ADA2. It has been established that in COPD patients the adenosine levels increase, which can contribute to decrease of ADA activity. In this research we studied the ADA and its isoenzyme activity in COPD patients. This descriptive analytical case-control study was performed on thirty patients who were hospitalized in the pulmonary wards with an acute exacerbation of COPD. ADA activity was determined in 30 COPD patients, 30 nonsmokers and 30 smokers controls. All subjects were male. We used colorimetric (Giusti) method for measuring of ADA activity. The data were analyzed using SPSS 13 software and Kruskall-Wallis and two-way ANOVA tests. Total ADA activity in the COPD and smoker control groups was significantly lower than in non smoker group (18.99 -/+ 7, 19.03 -/+ 9.1 and 22.95 -/+ 6.7 U/L, respectively). There was a significant difference for ADA2 between the three groups. Whereas the ADA1 activity in the three groups had no significant difference. Based on the obtained data, decrease of ADA activity may play an important role in the formation of pulmonary injury in COPD patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20548128     DOI: 09.01/ijaai.712

Source DB:  PubMed          Journal:  Iran J Allergy Asthma Immunol        ISSN: 1735-1502            Impact factor:   1.464


  7 in total

Review 1.  Adenosine signaling during acute and chronic disease states.

Authors:  Harry Karmouty-Quintana; Yang Xia; Michael R Blackburn
Journal:  J Mol Med (Berl)       Date:  2013-01-23       Impact factor: 4.599

2.  Altered Hypoxic-Adenosine Axis and Metabolism in Group III Pulmonary Hypertension.

Authors:  Luis J Garcia-Morales; Ning-Yuan Chen; Tingting Weng; Fayong Luo; Jonathan Davies; Kemly Philip; Kelly A Volcik; Ernestina Melicoff; Javier Amione-Guerra; Raquel R Bunge; Brian A Bruckner; Matthias Loebe; Holger K Eltzschig; Lavannya M Pandit; Michael R Blackburn; Harry Karmouty-Quintana
Journal:  Am J Respir Cell Mol Biol       Date:  2016-04       Impact factor: 6.914

3.  Adenosine Deaminase Activity in Chronic Lymphocytic Leukemia and Healthy Subjects.

Authors:  Bayazid Ghaderi; Sabrieh Amini; Farzad Maroofi; Chiya Jalali; Mitra Javanmardi; Daem Roshani; Mohammad Abdi
Journal:  Iran J Cancer Prev       Date:  2016-06-13

4.  The NLRP3 inflammasome is activated by nanoparticles through ATP, ADP and adenosine.

Authors:  L Baron; A Gombault; M Fanny; B Villeret; F Savigny; N Guillou; C Panek; M Le Bert; V Lagente; F Rassendren; N Riteau; I Couillin
Journal:  Cell Death Dis       Date:  2015-02-05       Impact factor: 8.469

5.  Imbalance in the Expression of Genes Associated with Purinergic Signalling in the Lung and Systemic Arteries of COPD Patients.

Authors:  Oriol Careta; Ester Cuevas; Mariana Muñoz-Esquerre; Marta López-Sánchez; Yuliana Pascual-González; Jordi Dorca; Elisabet Aliagas; Salud Santos
Journal:  Sci Rep       Date:  2019-02-26       Impact factor: 4.379

6.  Evaluation of adenosine deaminase (ADA) isoenzymes activity and tumor necrosis factor-α (TNFα) concentration in chronic heart failure.

Authors:  IrajI Khodadadi; Mohammad Saleh Vahedi; Mohammad Abdi; Nasrin Daneshkhah; Rezgar Rahbari; Shahoo Menbari; Dara Ahmadi; Abbas Ahmadi; Fariba Lahoorpour; Mohammad Saied Hakhamaneshi; Saman Javid; Bahram Nikkhoo
Journal:  EXCLI J       Date:  2014-02-03       Impact factor: 4.068

7.  Evaluation of Serum Adenosine Deaminase in Cystic Fibrosis Patients in an Iranian Referral Hospital.

Authors:  Fatemeh Farahmand; Parisa Tajdini; Gholamhossein Falahi; Sedigheh Shams; Shima Mahmoudi
Journal:  Iran J Pediatr       Date:  2016-02-10       Impact factor: 0.364

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.